JP2022510410A - 去勢抵抗性および去勢感受性前立腺がんを処置するための方法 - Google Patents

去勢抵抗性および去勢感受性前立腺がんを処置するための方法 Download PDF

Info

Publication number
JP2022510410A
JP2022510410A JP2021531722A JP2021531722A JP2022510410A JP 2022510410 A JP2022510410 A JP 2022510410A JP 2021531722 A JP2021531722 A JP 2021531722A JP 2021531722 A JP2021531722 A JP 2021531722A JP 2022510410 A JP2022510410 A JP 2022510410A
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
subject
prostate cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021531722A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022510410A5 (cg-RX-API-DMAC7.html
Inventor
スティーブン エル. ワーナー,
デイビッド ジェイ. ベアス,
スティーブン パトリック アンソニー,
マイケル ヴィンセント マッカラー,
Original Assignee
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド filed Critical スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド
Publication of JP2022510410A publication Critical patent/JP2022510410A/ja
Publication of JP2022510410A5 publication Critical patent/JP2022510410A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/30—Animals modified by surgical methods
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021531722A 2018-12-07 2019-12-06 去勢抵抗性および去勢感受性前立腺がんを処置するための方法 Pending JP2022510410A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862776985P 2018-12-07 2018-12-07
US62/776,985 2018-12-07
US201962909147P 2019-10-01 2019-10-01
US62/909,147 2019-10-01
US201962926390P 2019-10-25 2019-10-25
US62/926,390 2019-10-25
PCT/US2019/065069 WO2020118252A1 (en) 2018-12-07 2019-12-06 Methods for treating castration-resistant and castration- sensitive prostate cancer

Publications (2)

Publication Number Publication Date
JP2022510410A true JP2022510410A (ja) 2022-01-26
JP2022510410A5 JP2022510410A5 (cg-RX-API-DMAC7.html) 2022-11-29

Family

ID=70974424

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021531722A Pending JP2022510410A (ja) 2018-12-07 2019-12-06 去勢抵抗性および去勢感受性前立腺がんを処置するための方法

Country Status (9)

Country Link
US (2) US20200281949A1 (cg-RX-API-DMAC7.html)
EP (1) EP3891294A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022510410A (cg-RX-API-DMAC7.html)
KR (1) KR20210100145A (cg-RX-API-DMAC7.html)
CN (1) CN113164500A (cg-RX-API-DMAC7.html)
AU (1) AU2019395100A1 (cg-RX-API-DMAC7.html)
CA (1) CA3120850A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021005075A (cg-RX-API-DMAC7.html)
WO (1) WO2020118252A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10471023B2 (en) 2015-03-12 2019-11-12 British Columbia Cancer Agency Branch Bisphenol ether derivatives and methods for using the same
HUE045585T2 (hu) 2015-05-18 2020-01-28 Tolero Pharmaceuticals Inc Megnövelt biológiai hozzáférhetõséggel rendelkezõ Alvocidib gyógyszer-elõanyagok
US20170298033A1 (en) 2016-04-15 2017-10-19 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
JP7196160B2 (ja) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー, インコーポレイテッド Mcl-1阻害剤アルボシジブを用いた、bcl-2阻害剤に対して非感受性である癌の治療レジメン
US20190240198A1 (en) * 2018-02-05 2019-08-08 Dean G. Tang Formulations and methods for the treatment of cancers
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
JP2022525149A (ja) 2019-03-20 2022-05-11 スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置
US12109179B2 (en) 2019-03-28 2024-10-08 Essa Pharma Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
EP4135675A4 (en) 2020-04-17 2024-04-10 Essa Pharma, Inc. SOLID FORMS OF AN N-TERMINAL DOMAIN ANDROGEN RECEPTOR INHIBITOR AND USES THEREOF
CA3215182A1 (en) * 2021-04-16 2022-10-20 Han-Jie Zhou Pharmaceutical compositions comprising inhibitors of the androgen receptor and uses thereof
WO2023114264A1 (en) * 2021-12-15 2023-06-22 Eli Lilly And Company Combination for treatment of high-risk metastatic hormone-sensitive prostate cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017534248A (ja) * 2014-08-25 2017-11-24 ザ ジョンズ ホプキンズ ユニヴァーシティー 前立腺がん治療に関する方法及び組成物
JP2018517686A (ja) * 2015-05-18 2018-07-05 トレロ ファーマシューティカルズ, インコーポレイテッド バイオアベイラビリティが高いアルボシジブプロドラッグ

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001253618A1 (en) * 2000-04-21 2001-11-07 Arch Development Corporation Flavopiridol drug combinations and methods with reduced side effects
HK1212683A1 (zh) * 2012-09-26 2016-06-17 Mannkind Corporation 多个激酶途径抑制剂
EP2945628B1 (en) * 2013-01-15 2020-04-15 Aragon Pharmaceuticals, Inc. Androgen receptor modulator in combination with abiraterone acetate and prednisone for treating prostate cancer
WO2018094275A1 (en) * 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
US11034710B2 (en) * 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017534248A (ja) * 2014-08-25 2017-11-24 ザ ジョンズ ホプキンズ ユニヴァーシティー 前立腺がん治療に関する方法及び組成物
JP2018517686A (ja) * 2015-05-18 2018-07-05 トレロ ファーマシューティカルズ, インコーポレイテッド バイオアベイラビリティが高いアルボシジブプロドラッグ

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BJU INT, vol. 113, JPN6023043528, 2014, pages 82 - 89, ISSN: 0005330401 *
CANCER RES, vol. 72, JPN6023043529, 2012, pages 8, ISSN: 0005330402 *
MOL CANCER THER, vol. 5, no. 5, JPN6023043531, 2006, pages 1216 - 1226, ISSN: 0005178025 *
MOL ENDOCRINOL, vol. 24, JPN6023043530, 2010, pages 2267 - 2280, ISSN: 0005330403 *

Also Published As

Publication number Publication date
KR20210100145A (ko) 2021-08-13
US20220339172A1 (en) 2022-10-27
CA3120850A1 (en) 2020-06-11
WO2020118252A1 (en) 2020-06-11
EP3891294A1 (en) 2021-10-13
AU2019395100A1 (en) 2021-06-03
EP3891294A4 (en) 2022-09-07
US20200281949A1 (en) 2020-09-10
MX2021005075A (es) 2021-07-15
CN113164500A (zh) 2021-07-23

Similar Documents

Publication Publication Date Title
US20220339172A1 (en) Methods for treating castration-resistant and castration-sensitive prostate cancer
US12077554B2 (en) CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
JP2022017295A (ja) Hdac阻害剤とpd-l1阻害剤との組み合わせ療法
US20160375044A1 (en) Compositions and Methods for Inhibiting Arginase Activity
TW201740979A (zh) 熱休克蛋白(hsp)90抑制劑藥物共軛物
TWI873485B (zh) 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案
CN109819649B (zh) 氨基嘌呤化合物的固体形式及其使用方法
JP2021524835A (ja) Axlキナーゼ阻害剤およびその使用
USRE50319E1 (en) Compounds and methods for treating cancer
TW202210076A (zh) 組合療法
JP2018138570A (ja) 癌の治療のためのamg900の使用
EP4034242B1 (en) New active agent for use in the treatment or prevention of immune checkpoint inhibitor-induced colitis
TWI857119B (zh) 治療癌症之方法
CN102149725A (zh) 用于抑制g2细胞周期停滞和使细胞对dna损伤剂敏感的cbp501衍生制剂及基于其的方法
JP2025504558A (ja) Psma標的化放射性医薬品およびチェックポイント阻害剤併用療法
CN112020362A (zh) 治疗癌症的方法
US20220296557A1 (en) Combinations of bcl-2/bcl-xl inhibitors and related uses
CN111757737B (zh) 用于治疗三阴性乳腺癌的喹啉衍生物
JP2025503213A (ja) Ntsr1標的化放射性医薬品およびチェックポイント阻害剤併用療法
RU2806635C2 (ru) Комбинированная терапия, включающая соединение ацилтиомочевины и абиратерон
WO2025202971A1 (en) Kras g12c inhibitor for use for the treatment of non-small cell lung cancer
WO2025203012A1 (en) Kras g12c inhibitor for use for the treatment of non-small cell lung cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221118

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231020

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231025

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240524